A5054320718- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Advanced Breast Cancer Therapies
- Time Series Analysis and Forecasting
- Male Breast Health Studies
- Hepatitis B Virus Studies
- Cancer and Skin Lesions
- Head and Neck Cancer Studies
- Bayesian Methods and Mixture Models
- Global Cancer Incidence and Screening
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Advanced Clustering Algorithms Research
- Cancer Immunotherapy and Biomarkers
- Advanced Statistical Methods and Models
- Neuroinflammation and Neurodegeneration Mechanisms
- Hepatitis C virus research
- Spectroscopy and Chemometric Analyses
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Immune Response and Inflammation
Janssen (Belgium)
2020-2024
Hasselt University
2021
European Organisation for Research and Treatment of Cancer
2012-2019
Breast International Group
2016-2018
Ontario Institute for Cancer Research
2018
Cancer Trials Ireland
2018
Cornell University
2018
European Organisation for Research and Treatment of Cancer
2012-2017
Institut Bergonié
2012-2017
Institut Jules Bordet
2012-2017
The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought provide prospective evidence the utility addition standard clinical–pathological criteria selecting patients for adjuvant chemotherapy.
The current debate on overdiagnosis and overtreatment of screen-detected ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue. A substantial number DCIS lesions will never form a health hazard, particularly if it concerns non- slow-growing low-grade DCIS. LORD study aims evaluate safety active surveillance women with low-risk DCIS.This is randomised, international multicentre, open-label, phase III non-inferiority trial, led by Dutch Breast Cancer...
This article defines and studies a depth for multivariate functional data. By the nature by including weight function, it acknowledges important characteristics of data, namely differences in amount local amplitude, shape, phase variation. We study both population finite sample versions. The curves may include warping functions, derivatives, integrals original better overall representation data via depth. present simulation examples that confirm good performance this function. Supplementary...
LBA1001 The full, final text of this abstract will be available at abstract.asco.org 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to June 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
Abstract Withdrawn by Author Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-20.
LBA1001 Background: Sentinel node biopsy (SNB) is standard in assessing axillary lymph status for cN0 breast cancer patients. In case of a positive SNB, if treatment advised, dissection (ALND) the current standard. Although ALND provides excellent regional control, it may give harmful side effects. Axillary radiotherapy (ART) instead was hypothesized to provide comparable control and less Methods: From 2001 2010, patients with cT1E2N0 primary were enrolled EORTC phase III non-inferiority...
Overdiagnosis of breast cancer, i.e. the detection slow-growing tumors that would never have caused symptoms or death, became more prevalent with implementation population-based screening. Only rough estimates been made proportion patients are overdiagnosed and identification those is difficult. Therefore, aim this study to evaluate whether tumor biology can help identify screen-detected at such a low risk recurrence they likely be overdiagnosed. Furthermore, we wish impact transition from...
We explored, within the EORTC10994 study, outcomes for patients with molecular apocrine (MA) breast cancer, and defined immunohistochemistry (IHC) as androgen-receptor (AR) positive, oestrogen (ER) progesterone (PR) negative. also assessed concordance between IHC gene expression arrays (GEA) in identification of MA cancers. Centrally biopsies AR, ER, PR, HER2 Ki67 by were classified into six subtypes: MA, triple-negative (TN) basal-like, luminal A, B negative, positive "other". The two main...
Abstract Background: Pathologic complete response (pCR) is a proposed surrogate endpoint for predicting long-term clinical benefit on endpoints such as disease-free survival (DFS), event-free (EFS), or overall (OS). A meta-analysis needed to establish the magnitude of pCR improvement trial level that results in improved DFS, EFS, OS. Methods: We identified 12 neoadjuvant randomized trials (N = 13,125) with clearly defined and follow-up available EFS Trials included AGO 1 (n 668), ECTO 1355),...
Abstract Intro: Male BC is a rare disease (<1% male tumors); knowledge limited and management extrapolated from female BC. An international consortium, coordinated by EORTC TBCRC, was created to better characterize manage this disease, with 3 parts: 1) retrospective joint analysis 2) prospective registry 3) clinical trial(s). We report 1st results of part 1. Methods: Joint pts available FU & FFPE samples, treated in 1990-2010, 23 centers 9 countries. Clinical data, long term...
Summary Warping is an approach to the reduction and analysis of phase variability in functional observations, by applying a smooth bijection function argument. We propose natural representation warping functions terms new type elementary named ‘warping component functions’, or ‘warplets’, which are combined into composition. The inverse trivial explicit obtain. A sequential Bayesian estimation strategy introduced fits series models transfers posterior previous fit prior next fit. Model...
Abstract Background: The MINDACT TRIAL investigated the clinical utility of 70-gene profile (MammaPrint®), when confronted to standard pathological (CP) criteria, for selection patients unlikely benefit from adjuvant chemotherapy (CT).Methods: From 2007 2011, 11288 were screened in 112 centers 9 countries, whom 6693 enrolled. Enrolled had undergone successful determination their genomic risk G (with MammaPrint®) and C (modified version Adjuvant! Online). Patients evaluated as “low risk”, if...
Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding differences between methods can lead an improved ER, PgR, and HER-2 assessment. The purpose this preplanned translational research investigate the correlation central IHC/FISH assessments with microarray mRNA readouts status in MINDACT trial determine if any discordance could be attributed intratumoral heterogeneity or DCIS normal tissue components...